The international journal
publishes research results by Zhang Zhijiang et al of the College
of Public Health（2011-10-18）
The international authoritative
journal in the field of diabetes Diabetes Care (influence factor
7.141) published in its October issue an article by Zhang Zhijiang
et al of the College of Public Health of Shanghai Jiaotong
University entitled “The administering of dimethyldiguanide
effectively lowers the risk of intestinal cancer,‘ together with an
editorial note highly praising the importance of the
Diabetes II is
also known as diabetes that develops in later life, which often
occurs between ages 35 to 40, accounting for 90% of the cases.
During the period of 2007 and 2008, the incidence of diabetes among
adults over the age of 20 reached 9.7%, People in a prestage
reached 15.5%. According to ”Nutritional and Health Conditions of
the Chinese Populace“ published in 2010, the incidence of diabetes
II ranked first in the world.
Figures of the
past studies show that diabetics have a 1.2 to 2.5 times higher
incidence of cancer than the average. As diabetics are less able to
receive major surgery, or to withstand the effects of chemotherapy,
thus with a poorer prognosis than non-diabetic patients with
cancer, it is imperative to lower the risk of cancer while
controlling the development of diabetes, an important research
subject for researchers. By means of meta-analysis, Doctor Zhang
Zhijiang collected and examined a large sample of diabetes II
patients from all over the world (108161 cases) and found that
patients who took dimethyldiguanide showed markedly lower risk of
intestinal cancer than those who did not.
dimethyldiguanide is an orally administered medication
lowering blood sugar in diabetes, used in diabetes II patients not
adequately responsive to dietary and exercise regimen. It can be
used separately or in combination with tolbutamide and insuline.
First introduced in 1920s, dimethyldiguanide, already in use for
nearly 100 years, has the advantages of clear efficacy, reasonable
price, fewer side-effects and no antagonism in polypharmacy.
Dimethyldiguanide, a front-line medication in the treatment of
diabetes, produces good results in severe diabetics and those with
accompanying hyperinsulinism. Due to the fact that in some parts of
China, the diagnosis of diabetes is often delayed or the disease
process is prolonged, dimethyldiguanide is often replaced by other
orally-administered medications with more marked effect of lowering
blood sugar or insulin, Dr. Zhang pointed out ”the need to test
this hypothesis through more rigidly-designed researches.“ ”If, as
we have found, dimethyldiguanide does effectively lower the risk of
intestinal cancer, it would mean that the majority of diabetics who
are not contraindicated for the use of dimethyldiguanide should at
least include dimethyldiguanide in the treatment.
As pointed out
in the editorial note, the research also revives an age-old,
conventional medication. Whether dimethyldiguanide can lower the
incidence of intestinal cancer in the healthy population, whether
it lowers the rate of relapse in patients with intestinal cancer,
or even whether it can fight again other malignancies, definitely
points to the direction of further research.